The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Pancreatic Adenocarcinoma: FOLFIRINOX Combination Chemotherapy

Aggressive multi-agent regimen for fit patients with metastatic or locally advanced disease

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Pancreatic Adenocarcinoma: FOLFIRINOX Combination Chemotherapy?

FOLFIRINOX combination chemotherapy includes 5-fluorouracil bolus and infusion, leucovorin, irinotecan and oxaliplatin administered every 2 weeks.

Indications include metastatic pancreatic adenocarcinoma, locally advanced unresectable disease, neoadjuvant therapy for borderline resectable and adjuvant therapy after resection.

Modified FOLFIRINOX with reduced doses or omission of bolus 5-FU is increasingly used to improve tolerability.

Patient selection requires good performance status (ECOG 0-1), adequate organ function, age generally less than 76 years and absence of significant comorbidities.

Treatment continues until disease progression, unacceptable toxicity or completion of planned cycles in adjuvant or neoadjuvant settings.

Symptoms

Significant hematologic toxicity with neutropenia, anemia and thrombocytopenia requires monitoring and supportive care.
Gastrointestinal effects including diarrhea, nausea, vomiting, mucositis and abdominal pain commonly require management.
Peripheral neuropathy from oxaliplatin develops cumulatively often becoming dose-limiting.
Fatigue, alopecia and dermatologic effects commonly impact quality of life.
Less common but serious effects include cardiotoxicity, hepatotoxicity, pulmonary toxicity and severe infections.

Risk Factors

Compromised performance status with reduced ability to tolerate intensive chemotherapy.
Age greater than 76 years with limited evidence base for optimal regimen modifications.
Significant comorbidities including cardiac, renal, hepatic or pulmonary disease.
Pre-existing peripheral neuropathy may worsen significantly with oxaliplatin.
Inadequate biliary drainage in patients with biliary obstruction may complicate liver toxicity assessment.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Severe diarrhea, dehydration or signs of bowel obstruction require urgent oncologic evaluation.
  • Fever, particularly with neutropenia, requires immediate hospitalization and antimicrobial therapy.
  • New or worsening neuropathy may require dose reduction or discontinuation of oxaliplatin.
  • Cardiac symptoms including chest pain or arrhythmias require cardiac evaluation.
  • Severe nausea, vomiting or oral intake limitations require hospitalization for hydration and supportive care.

Treatment Methods

01
Comprehensive baseline evaluation including performance status, organ function, nutritional status and patient counseling.
02
Aggressive antiemetic prophylaxis, growth factor support and supportive care management.
03
Dose modifications for toxicity guided by NCI CTCAE grading with treatment delays as needed.
04
Comprehensive symptom management with multidisciplinary team including palliative care, nutrition support and psychosocial care.
05
Treatment monitoring with imaging assessment every 2-3 months, tumor marker (CA 19-9) follow-up, comprehensive supportive care addressing pain, malnutrition and quality of life along with consideration of subsequent line therapies (gemcitabine-nab-paclitaxel, NALIRIFOX) and clinical trial enrollment optimizes outcomes for this challenging malignancy.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.